分子靶向药物在肝细胞肝癌治疗中的研究进展  

The progress of molecular targeted drugs for advanced hepatocecullar carcinoma

作　　者：聂艳丽[1] 南克俊[2] 

机构地区：[1]湖北省肿瘤医院腹部肿瘤内科,湖北武汉430079 [2]西安交通大学第一附属医院肿瘤内科,陕西西安710061

出　　处：《现代肿瘤医学》2014年第8期1996-1999,共4页Journal of Modern Oncology

摘　　要：对于不适宜手术切除的晚期肝细胞肝癌,传统的化疗并不能改善患者的预后。分子靶向药物的出现为肝细胞肝癌的治疗提供了新的治疗手段。分子靶向药物治疗肝细胞肝癌的临床试验中,包括多靶点抑制剂、血管内皮生长抑制剂、小分子酪氨酸激酶抑制剂以及分子靶向药与化疗的联合等已经显示出了潜在的疗效和良好的发展前景。临床试验显示索拉非尼可延长肝细胞肝癌的中位无疾病进展时间至9.2个月,中位总生存至10.5个月,贝伐单抗与厄洛替尼联合治疗肝细胞肝癌延长中位总生存达68周。本文针对肝细胞肝癌使用多靶点抑制剂、血管内皮生长抑制剂等的临床研究进展进行综述。Hepatocecullar carcinoma is one of the common malignancy which often presents at a stage of unresce-table,traditional chemotherapy can not improve the prognosis of patients. Molecular - targeted therapy is a new method and tendency in the treatment of hepatocellular carcinoma（HCC）. Early studies of targeted therapies,including mul-tikinase inhibitors and inhibiting angiogenesis,Tyrosine kinase inhibitor and molecular targeted drugs combined with chemotherapy,have shown effective and great perspective. Results of clinical trails show that sorafenib prolongs medi-an progression - free survival and overall survival up to 9. 2 and 10. 5 months,respectively. Bevacizumab combined with erlotinib even makes median OS reach 68 weeks. This review summarizes newly outcome of clinical trials of multi- kinase inhibitors and anti - angiogenesis and other molecular - targeted drugs for hepatocecullar carcinoma.

关 键 词：晚期肝细胞肝癌 靶向治疗 索拉非尼 贝伐单抗 

分 类 号：R735.7[医药卫生—肿瘤]